Innate immune factor in host susceptibility to rift valley fever virus
宿主对裂谷热病毒易感性的先天免疫因素
基本信息
- 批准号:8234941
- 负责人:
- 金额:$ 48.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAffectAfricaAfrica South of the SaharaAgeAnimal ModelAntibodiesAntigensArbovirusesAreaAttenuatedBioterrorismBloodBreathingCD8B1 geneCategoriesCellular ImmunityChronic DiseaseClinicalClinical ResearchCommunitiesCulicidaeDemographic FactorsDendritic CellsDevelopmentDiseaseDisease OutcomeEncephalitisEndotheliumEnvironmental Risk FactorEpidemicEpitheliumEpitopesEventExposure toGene FrequencyGeneticGenetic PolymorphismGenetic Predisposition to DiseaseHeterogeneityHumanImmuneImmune responseImmunityImmunoglobulin GIn VitroInfectionIntegration Host FactorsInterferon-alphaInterferonsInvestigationKenyaKnowledgeLaboratoriesLigandsLinkLivestockMaintenanceMediatingMiddle EastMorbidity - disease rateMucous MembraneNatural ImmunityOralOrthobunyavirusOutcomeParticipantPathogenesisPathologyPathway interactionsPatientsPeripheral Blood Mononuclear CellPersonsPhenotypePopulationPositioning AttributePredispositionPrimatesProteinsRNARNA HelicaseRecording of previous eventsRecoveryRetinalRetinal DiseasesRetinitisRift Valley fever virusRiskRisk FactorsRoleRouteSamplingSerologicalSeveritiesSiteSpecific qualifier valueStructure of retinal pigment epitheliumStudy SubjectSystemT memory cellT-Cell ActivationT-LymphocyteTLR3 geneTestingTranslational ResearchUp-RegulationVenousViralViral Hemorrhagic FeversViral Nonstructural ProteinsViremiaVirusVirus Diseasesadaptive immunityaerosolizedanimal tissuebasebiodefensecellular targetingclinical phenotypeconjunctivadisease phenotypeepizooticfeedinghigh riskin vitro Modellifetime riskmortalitynovelpathogenresponsetransmission processtripolyphosphatevirus envelope
项目摘要
Rift Valley fever virus is a Category A arbovirus pathogen that causes hemorrhagic fever, retinitis and
encephalitis in Africa and the Middle East. The virus has high potential for deliberate release and
bioterrorism since it may be aerosolized and transmitted by inhalation or contact with mucosal tissue as well
as by blood-feeding mosquitoes. Given the lack of a small animal model that faithfully recapitulates the
diverse outcomes of human infection and the fact that RVF epidemics occur in remote areas, little is known
about how innate immune events contribute to disease pathogenesis and protective adaptive immunity aside
from limited observations that delayed type I IFN responses are associated with severe illness and mortality.
These gaps in knowledge will be addressed by combining study of residents of an area of Kenya where RVF
epidemics occur in ~8-year cycles (most recently 2006-2007) with in vitro models of infection and disease
pathogenesis. We have observed that RVFV transmission to humans in this area is much greater than
previously suspected, both during epidemic and inter-epidemic periods, with up to 25% lifetime risk of
infection. In Specific Aim 1 we will define the risk factors for and spectrum of chronic disease phenotypes
(primarily retinitis) in persons infected during earlier, repeated RVF epidemics and pre-position the
necessary systems to test panels of patients with and without RVF-associated encephalitis and/or
hemorrhagic fever during the next epidemic. In Specific Aim 2 we will use in vitro models to define the innate
immune pathways, e.g. TLR and RNA helicases, affected by attenuated RVFV, identify key cellular targets at
sites of viral inoculation, dissemination and pathogenesis, e.g. oral and conjunctiva epithelium, dendritic
cells, retinal pigmented epithelium and venous endothelium, and examine how attenuated RVFV alters the
ability of dendritic cells to present antigen to T cells. In Specific Aim 3 we will examine the relationship
between serologic markers of prior infection and RVFV-specific CD4+ and CD8+ T cell memory, identify viral
epitopes that elicit T cell memory, and correlate in vitro PBMC innate and adaptive immune responses to
RVFV epitopes with the development of retinitis. In Specific Aim 4 we will determine how genetic
polymorphism of innate immunity accounts for heterogeneity in retinitis outcomes and adaptive immunity.
Overall this project will provide novel information regarding how innate and adaptive immunity to RVFV
determines infection and disease outcomes in humans at high-risk for exposure to this Category A pathogen.
裂谷热病毒是一种A类虫媒病毒病原体,可引起出血热、视网膜炎和
非洲和中东的脑炎。这种病毒极有可能被故意释放,
生物恐怖主义,因为它也可以通过吸入或与粘膜组织接触而雾化和传播
就像吸血蚊子一样由于缺乏一个小动物模型,忠实地概括了
由于人类感染的结果多种多样,而且裂谷热流行病发生在偏远地区,
关于先天免疫事件如何有助于疾病的发病机制和保护性适应性免疫
从有限的观察,延迟I型IFN反应与严重疾病和死亡率有关。
将通过对肯尼亚一个地区的居民进行研究来弥补这些知识上的差距,该地区存在裂谷热,
流行病以约8年为一个周期(最近的一次是2006-2007年)发生,采用体外感染和疾病模型
发病机制我们观察到RVFV在该地区传播给人类的比例远远高于
以前怀疑,无论是在流行和流行之间的时期,高达25%的终身风险,
感染在具体目标1中,我们将定义慢性病表型的风险因素和谱
(主要是视网膜炎),并预先定位
必要的系统,以测试患有和不患有RVF相关脑炎的患者组,和/或
在下一次流行病期间出现出血热。在具体目标2中,我们将使用体外模型来定义先天性
受减毒RVFV影响的免疫途径,例如TLR和RNA解旋酶,鉴定了
病毒接种、传播和发病部位,例如口腔和结膜上皮,树突状细胞
细胞,视网膜色素上皮和静脉内皮细胞,并检查如何衰减RVFV改变
树突状细胞向T细胞呈递抗原的能力。在具体目标3中,我们将研究
在先前感染的血清学标志物与RVFV特异性CD 4+和CD 8 + T细胞记忆之间,
表位,引发T细胞记忆,并在体外PBMC先天性和适应性免疫反应,
RVFV表位与视网膜炎的发展。在具体目标4中,我们将确定遗传
先天免疫的多态性解释了视网膜炎结果和适应性免疫的异质性。
总的来说,这个项目将提供新的信息,关于先天性和适应性免疫RVFV
确定暴露于这种A类病原体的高风险人群的感染和疾病结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Walter Kazura其他文献
James Walter Kazura的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James Walter Kazura', 18)}}的其他基金
Impact of Environmental Modifications on Pathogenesis and Immunity of Plasmodium falciparum and P. vivax Malaria
环境改造对恶性疟原虫和间日疟原虫疟疾发病机制和免疫的影响
- 批准号:
10608071 - 财政年份:2017
- 资助金额:
$ 48.18万 - 项目类别:
Impact of Environmental Modifications on Pathogenesis and Immunity of Plasmodium falciparum and P. vivax Malaria
环境改造对恶性疟原虫和间日疟原虫疟疾发病机制和免疫的影响
- 批准号:
10382276 - 财政年份:2017
- 资助金额:
$ 48.18万 - 项目类别:
Kruppel-Like Factor 2 Counters Vascular and Immunologic Dysfunction in Child Cerebral Malaria
Kruppel 样因子 2 可对抗儿童脑型疟疾的血管和免疫功能障碍
- 批准号:
10084256 - 财政年份:2017
- 资助金额:
$ 48.18万 - 项目类别:
Naturally Acquired Immunity to Malaria during the Epidemiologic Transition in Ken
肯恩流行病学转变期间对疟疾的自然获得免疫力
- 批准号:
8289398 - 财政年份:2011
- 资助金额:
$ 48.18万 - 项目类别:
Naturally Acquired Immunity to Malaria during the Epidemiologic Transition in Ken
肯恩流行病学转变期间对疟疾的自然获得免疫力
- 批准号:
8690756 - 财政年份:2011
- 资助金额:
$ 48.18万 - 项目类别:
Naturally Acquired Immunity to Malaria during the Epidemiologic Transition in Ken
肯恩流行病学转变期间对疟疾的自然获得免疫力
- 批准号:
8146459 - 财政年份:2011
- 资助金额:
$ 48.18万 - 项目类别:
Naturally Acquired Immunity to Malaria during the Epidemiologic Transition in Ken
肯恩流行病学转变期间对疟疾的自然获得免疫力
- 批准号:
8486389 - 财政年份:2011
- 资助金额:
$ 48.18万 - 项目类别:
Naturally Acquired Immunity to Malaria during the Epidemiologic Transition in Ken
肯恩流行病学转变期间对疟疾的自然获得免疫力
- 批准号:
8865541 - 财政年份:2011
- 资助金额:
$ 48.18万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 48.18万 - 项目类别:
Research Grant














{{item.name}}会员




